Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium lactis CNCM I-3446
- Development stage
- Unknown
- Lead developer
- Chr. Hansen
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium lactis CNCM I-3446 is a specific probiotic strain of *Bifidobacterium animalis* subsp. *lactis* deposited at the Collection Nationale de Cultures de Microorganismes (CNCM). It is primarily developed and utilized by Nestlé as a functional ingredient in infant formulas and nutritional supplements. The strain has been clinically investigated for its potential to modulate the intestinal microbiota and immune response in infants, specifically for the treatment and prevention of atopic dermatitis (eczema) and the progression of allergic diseases. Clinical trial data, including the ISRCTN41490500 study, have evaluated its efficacy as a dietary supplement in infants aged 3-6 months; however, results indicated no significant benefit in reducing eczema severity (SCORAD scores) compared to placebo when administered alongside standard topical treatments.
- Other names
- Bifidobacterium animalis subsp. lactis CNCM I-3446B. lactis CNCM I-3446
Beyond the preview
Go deeper on bifidobacterium lactis CNCM I-3446.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium lactis CNCM I-3446.